Shares of Surface Oncology Inc (NASDAQ:SURF) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price objective of $26.00 for the company, according to Zacks. Zacks has also given Surface Oncology an industry rank of 121 out of 255 based on the ratings given to its competitors.

Several research firms recently commented on SURF. Cowen restated a “buy” rating on shares of Surface Oncology in a report on Wednesday, June 13th. Evercore ISI began coverage on shares of Surface Oncology in a report on Monday, May 14th. They issued an “outperform” rating and a $26.00 price target on the stock. Goldman Sachs Group began coverage on shares of Surface Oncology in a report on Monday, May 14th. They issued a “neutral” rating and a $17.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Surface Oncology from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Tuesday, July 24th.

NASDAQ SURF opened at $9.75 on Tuesday. Surface Oncology has a one year low of $9.61 and a one year high of $18.18.

Surface Oncology (NASDAQ:SURF) last posted its quarterly earnings results on Tuesday, May 29th. The company reported $1.05 EPS for the quarter. The business had revenue of $45.50 million during the quarter. analysts expect that Surface Oncology will post -2.67 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of SURF. Atlas Venture Associates IX LLC purchased a new stake in shares of Surface Oncology during the second quarter valued at approximately $75,767,000. NEA Management Company LLC purchased a new stake in shares of Surface Oncology during the second quarter valued at approximately $54,070,000. FMR LLC purchased a new stake in shares of Surface Oncology during the second quarter valued at approximately $47,972,000. Citadel Advisors LLC purchased a new stake in shares of Surface Oncology during the second quarter valued at approximately $14,119,000. Finally, BlackRock Inc. purchased a new stake in shares of Surface Oncology during the second quarter valued at approximately $10,230,000. Institutional investors own 19.07% of the company’s stock.

Surface Oncology Company Profile

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.

Further Reading: What does RSI mean?

Get a free copy of the Zacks research report on Surface Oncology (SURF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.